Skip to main content

Table 5 Subgroup analyses by cancer type under the heterozygotic, dominant and recessive models

From: Association of human XPA rs1800975 polymorphism and cancer susceptibility: an integrative analysis of 71 case–control studies

Models

Subgroup

Study number (case/control)

OR (95% CI)

z

P

Heterozygotic model (AG vs. AA)

Lung cancer

19 (5004/9162)

0.86 (0.76–0.97)

2.46

0.014

LSCC

3 (878/19,47)

0.79 (0.64–0.97)

2.23

0.026

NSCLC

3 (928/1766)

0.78 (0.62–0.97)

2.19

0.029

LA

3 (968/1947)

0.84 (0.67–1.06)

1.45

0.147

Breast cancer

6 (2530/2940)

1.04 (0.79–1.38)

0.30

0.761

Digestive system cancer

18 (4038/6811)

1.05 (0.85–1.30)

0.48

0.634

Esophageal cancer

10 (2515/4002)

0.93 (0.70–1.23)

0.52

0.602

ESCC

4 (1136/2239)

0.88 (0.58–1.34)

0.59

0.554

Gastric cancer

4 (828/1495)

1.14 (0.71–1.82)

0.54

0.589

Colorectal cancer

3 (593/1021)

1.46 (1.02–2.11)

2.04

0.041

Reproductive system cancer

5 (1429/1756)

1.02 (0.81–1.28)

0.17

0.867

Endometrial cancer

3 (1182/1244)

0.94 (0.72–1.23)

0.45

0.656

Head and neck cancer

4 (886/2289)

0.95 (0.74–1.22)

0.39

0.694

Skin cancer

6 (3874/3826)

1.18 (1.02–1.36)

2.18

0.029

Skin BCC

3 (1852/1669)

1.14 (0.92–1.42)

1.17

0.241

Dominant model (AG + GG vs. AA)

Lung cancer

19 (5004/9162)

0.87 (0.77–0.98)

2.30

0.021

LSCC

3 (878/19,47)

0.80 (0.63–1.01)

1.86

0.062

NSCLC

3 (928/1766)

0.83 (0.64–1.07)

1.46

0.145

LA

3 (968/1947)

0.88 (0.71–1.09)

1.20

0.230

Breast cancer

6 (2530/2940)

1.04 (0.78–1.40)

0.28

0.782

Digestive system cancer

18 (4038/6811)

1.14 (0.89–1.44)

1.04

0.297

Esophageal cancer

10 (2515/4002)

1.01 (0.72–1.43)

0.06

0.953

ESCC

4 (1136/2239)

0.99 (0.60–1.65)

0.02

0.982

Gastric cancer

4 (828/1495)

1.16 (0.71–1.89)

0.58

0.561

Colorectal cancer

3 (593/1021)

1.54 (1.08–2.20)

2.41

0.016

Reproductive system cancer

5 (1429/1756)

1.07 (0.87–1.32)

0.63

0.528

Endometrial cancer

3 (1182/1244)

1.01 (0.75–1.37)

0.09

0.926

Head and neck cancer

4 (886/2289)

1.02 (0.81–1.29)

0.16

0.873

Skin cancer

6 (3874/3826)

1.27 (1.10–1.45)

3.36

0.001

Skin BCC

3 (1852/1669)

1.25 (1.00–1.56)

1.98

0.048

Recessive model (GG vs. AA + AG)

Lung cancer

19 (5004/9162)

0.99 (0.90–1.08)

0.31

0.755

LSCC

3 (878/19,47)

0.97 (0.81–1.16)

0.35

0.726

NSCLC

3 (928/1766)

1.08 (0.72–1.62)

0.39

0.700

LA

3 (968/1947)

1.05 (0.87–1.27)

0.51

0.613

Breast cancer

6 (2530/2940)

0.98 (0.77–1.24)

0.20

0.842

Digestive system cancer

20 (4340/7157)

1.26 (1.03–1.54)

2.24

0.025

Esophageal cancer

10 (2515/4002)

1.28 (0.89–1.83)

1.32

0.186

ESCC

4 (1136/2239)

1.35 (0.81–2.27)

1.15

0.249

Gastric cancer

4 (828/1495)

1.05 (0.79–1.40)

0.33

0.739

Colorectal cancer

5 (895/1367)

1.22 (0.95–1.56)

1.59

0.111

Reproductive system cancer

5 (1429/1756)

1.16 (1.00–1.34)

1.91

0.056

Endometrial cancer

3 (1182/1244)

1.18 (0.97–1.44)

1.65

0.098

Head and neck cancer

4 (886/2289)

1.15 (0.94–1.41)

1.39

0.165

Skin cancer

6 (3874/3826)

1.20 (1.09–1.31)

3.93

< 0.001

Skin BCC

3 (1852/1669)

1.23 (1.07–1.40)

2.99

0.003

  1. OR odds ratio, CI confidence interval, LSCC lung squamous cell carcinoma, NSCLC non-small cell lung cancer, LA lung adenocarcinoma
  2. ESCC esophageal squamous cell carcinoma, BCC basal cell carcinoma